PHENTERMINE HYDROCHLORIDE; TOPIRAMATE | A204982 | ACTAVIS LABORATORIES FL INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
VIVUS, INC. v. ACTAVIS LABORATORIES FL, INC. 6 patentsANDA 204982phentermine and topiramate extended-release | D.N.J. | 2014-06-12 | Terminated 2017-07-07 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$3.41
per ea
Lowest NADAC/Unit
$3.03
per ea
Brand NDCs
0
Generic NDCs
4
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00480329556PHENTERMINE-TOPIRAMATE ER 15-92 MG CAPSULE | $3.41 | EA | Generic | — | 2026-06-17 |
| 00480329656PHENTERMINE-TOPIRAMATE ER 7.5-46 MG CAPSULE | $3.37 | EA | Generic | — | 2026-06-17 |
| 00480329756PHENTERMINE-TOPIRAMATE ER 3.75-23 MG CAPSULE | $3.30 | EA | Generic | — | 2026-06-17 |
| 00480229956PHENTERMINE-TOPIRAMATE ER 11.25-69 MG CAPSULE | $3.03 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.